RT Journal Article SR Electronic T1 ACE2 expression in adipose tissue is associated with COVID-19 cardio-metabolic risk factors and cell type composition JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.08.11.20171108 DO 10.1101/2020.08.11.20171108 A1 Julia S. El-Sayed Moustafa A1 Anne U. Jackson A1 Sarah M. Brotman A1 Li Guan A1 Sergio Villicaña A1 Amy L. Roberts A1 Antonino Zito A1 Lori Bonnycastle A1 Michael R. Erdos A1 Narisu Narisu A1 Heather M. Stringham A1 Ryan Welch A1 Tingfen Yan A1 Timo Lakka A1 Stephen Parker A1 Jaakko Tuomilehto A1 Francis S. Collins A1 Päivi Pajukanta A1 Michael Boehnke A1 Heikki A. Koistinen A1 Markku Laakso A1 Mario Falchi A1 Jordana T. Bell A1 Laura J. Scott A1 Karen L. Mohlke A1 Kerrin S. Small YR 2020 UL http://medrxiv.org/content/early/2020/08/14/2020.08.11.20171108.abstract AB COVID-19 severity has varied widely, with demographic and cardio-metabolic factors increasing risk of severe reactions to SARS-CoV-2 infection, but the underlying mechanisms for this remain uncertain. We investigated phenotypic and genetic factors associated with subcutaneous adipose tissue expression of Angiotensin I Converting Enzyme 2 (ACE2), which has been shown to act as a receptor for SARS-CoV-2 cellular entry. In a meta-analysis of three independent studies including up to 1,471 participants, lower adipose tissue ACE2 expression was associated with adverse cardio-metabolic health indices including type 2 diabetes (T2D) and obesity status, higher serum fasting insulin and BMI, and lower serum HDL levels (P<5.32×10-4). ACE2 expression levels were also associated with estimated proportions of cell types in adipose tissue; lower ACE2 expression was associated with a lower proportion of microvascular endothelial cells (P=4.25×10-4) and higher macrophage proportion (P=2.74×10-5), suggesting a link to inflammation. Despite an estimated heritability of 32%, we did not identify any proximal or distal genetic variants (eQTLs) associated with adipose tissue ACE2 expression. Our results demonstrate that at-risk individuals have lower background ACE2 levels in this highly relevant tissue. Further studies will be required to establish how this may contribute to increased COVID-19 severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMedical Research Council (MR/M004422/1 and MR/R023131/1). Wellcome Trust Medical Research Council European Union Chronic Disease Research Foundation (CDRF) Zoe Global Ltd The National Institute for Health Research (NIHR)-funded BioResource Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. US National Institutes of Health (NIH) grants U01DK062370 / 1-ZIA-HG000024 / R01DK093757 / R01DK072193 / P01HL28481 / and Academy of Finland Grants 271961 / 272741 and 258753. SMB was supported in part by a grant from the National Institute of General Medical Sciences under award 5T32 GM007092 and acknowledges the Global Partnership Award and UNC Global for travel funds. SV is supported by the National Council of Science and Technology of Mexico (CONACYT).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The TwinsUK project was approved by the ethics committee at St Thomas' Hospital London, where all the biopsies were carried out. Volunteers gave informed consent and signed an approved consent form prior to the biopsy procedure. Volunteers were supplied with an appropriate detailed information sheet regarding the research project and biopsy procedure by post prior to attending for the biopsy. The FUSION study was approved by the coordinating ethics committee of the Hospital District of Helsinki and Uusimaa, and written informed consent was obtained from all participants. The METSIM study was approved by the Ethics Committee of the University of Eastern Finland and Kuopio University Hospital in Kuopio, Finland, and written informed consent was obtained from all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTwinsUK RNA-Seq data are deposited in the European Genome-phenome Archive (EGA) under accession EGAS00001000805. METSIM RNASeq data have been deposited in the Gene Expression Omnibus (GEO) under accession GSE135134. The dbGaP accession number for the FUSION Tissue Biopsy Study is phs001048.v2.p1.